NEW YORK and SYDNEY , Feb. 12, 2020 /PRNewswire/ -- EnGeneIC Limited , a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the Company was featured in the publication InsightsCare
| NEW YORK and SYDNEY, Feb. 12, 2020 /PRNewswire/ -- EnGeneIC Pty Ltd a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the Company was featured in the publication InsightsCare as one of the 10 most innovative healthcare nanotech companies to watch. The December 2019 Issue (Vol 12) describes the convergence of nanotechnology and medicine and shines a spotlight on pioneering companies using nanotech to drive healthcare innovations.
EnGeneIC was selected based on the company’s development of its globally unique EDVTM nanocell, which can carry a payload directly to cancer cells while at the same time promoting an anti-tumour immune response. Added to this the nanocell has a relatively low cost of goods which makes it affordable to patients worldwide and it exhibits none of the attendant toxicity that synthetic particles exhibit. The Company has earned significant recognition in recent months, being named the 2019 Most Innovative Drug Delivery Company by Fierce Biotech and was awarded the 2019 Australian Financial Review “Most Innovative Company in Australia and New Zealand and Company with the Best Innovation and the Best Innovation Program.” To read the full InsightsCare article, click here. About EnGeneIC and the EDV™ Nanocell Technology For more information, please visit www.engeneic.com. Contact: or Johanna Bennett
SOURCE EnGeneIC |
View original content to download multimedia:
